View News

Top 12 stocks in focus: RIL, Glenmark Pharma, Axis Bank

Top 12 stocks in focus: RIL, Glenmark Pharma, Axis Bank

Check out the companies which will be in focus during trade today based on recent and latest news developments.

Glenmark Pharmaceuticals Ltd: Glenmark Pharmaceuticals announced that the Issuance Committee of the Company at its meeting held on May 31, 2016, has approved raising of up to USD 200 million through issuance of FCCBs to be listed on the Singapore Stock Exchange (Issue) and has decided to open/launch the Issue on May 31, 2016. 

Axis Bank: Axis Bank receives approval from RBI - FIIs / RFPIs can invest up to 62 per cent under Portfolio Investment Scheme (PIS)

ONGC Videsh Ltd: ONGC Videsh announced completion of acquisition of 15 per cent stake in Russia's second biggest oil field of Vankor from Rosneft for $1.268 billion, says report. 

Reliance Industries: Reliance Industries is running at lower capacity at some plants and is undertaking shut down of twonof its petrochemical units at Dahej in Gujarat in response to insufficient water to run the units.

DLF: DLF Utilities Ltd., (DUL), a subsidiary has executed an Amendment Agreement on 30th May, 2016 with PVR Limited in connection with sale of the cinema exhibition business (operated under the brand name of “DT Cinemas”) on a slump sale basis for a revised consideration of Rs.433 crore (Rs. 100 crore of which to be received upon satisfaction of certain Conditions Subsequent).

 

Oil stocks ibn focus: Oil marketing companies hiked petrol prices by Rs 2.58 per litre and diesel by Rs 2.26 per litre, with effect in Delhi from midnight.
 

Maruti Suzuki India Ltd: Maruti Suzuki India said it will resume production at its factories from 1 June, says report.

Thomas Cook (India): Thomas Cook has entered into a partnership with online budget hotels aggregator, Vista Rooms, for providing standardised accommodation experience.

Mahindra & Mahindra: M&M said it has entered into a brand licence agreement with Pininfarina for use of trademarks after closing the deal to acquire 76.06 per cent stake in the Turin-based company. 

Sun Pharmaceutical Industries: Sun Pharmais looking at up to 10 per cent increase in its consolidated revenues in the current financial year with an expectation of all round growth of business.

Add Comment

Cancel reply

Your email address will not be published. Required fields are marked *